PMID- 36760600
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230211
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - A Nomogram for Predicting Vision-Threatening Diabetic Retinopathy Among Mild 
      Diabetic Retinopathy Patients: A Case-Control and Prospective Study of Type 2 
      Diabetes.
PG  - 275-283
LID - 10.2147/DMSO.S394607 [doi]
AB  - AIM: This study aims to develop a nomogram for predicting vision-threatening 
      diabetic retinopathy (VTDR) in type 2 diabetes mellitus (T2DM) with mild 
      non-proliferative diabetic retinopathy (NPDR) patients. MATERIALS AND METHODS: In 
      case-control analysis, 440 patients with mild NPDR or VTDR were enrolled to 
      identify predictors and develop a nomogram. In the prospective cohort, 120 T2DM 
      patients with mild NPDR were enrolled for external validation. Sensitivity, 
      specificity, and area under the receiver operating characteristic (AUC) were 
      calculated to evaluate the predictive performance of the nomogram. RESULTS: In 
      case-control analysis, 2-h C-peptide (OR = 0.85, 95% CI: 0.75 to 0.95, p = 
      0.006), sural nerve conduction impaired (SNCI) (mildly: OR = 2.18, 95% CI: 1.10 
      to 4.33, p = 0.026; moderately/severely: 3.66, 95% CI: 1.74 to 7.70, p < 0.001) 
      and UACR (microalbuminuria: OR = 2.37, 95% CI: 1.25 to 4.48, p = 0.008; 
      macroalbuminuria: 4.02, 95% CI: 1.61 to 10.06, p = 0.003) were identified as 
      independent predictors. The concordance index of the prediction nomogram was 0.76 
      in the training set. In the test set, sensitivity, specificity, and AUC were 
      84.8%, 60.6%, and 0.73, respectively. In the prospective cohort, median follow-up 
      period was 42 months, and 15 patients (12.5%) developed VTDR. Sensitivity, 
      specificity, and AUC of prediction were 66.7%, 89.5%, and 0.75, respectively. 
      CONCLUSION: Introducing 2-h C-peptide, UACR, and SNCI, the nomogram demonstrated 
      a good discriminatory power for predicting risk of VTDR in mild NPDR individuals.
CI  - (c) 2023 Ke et al.
FAU - Ke, Jing
AU  - Ke J
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, 101149, People's Republic of China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, People's 
      Republic of China.
FAU - Li, Kun
AU  - Li K
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, 101149, People's Republic of China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, People's 
      Republic of China.
FAU - Cao, Bin
AU  - Cao B
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, 101149, People's Republic of China.
AD  - Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230127
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC9888403
OTO - NOTNLM
OT  - diabetic retinopathy
OT  - nomogram
OT  - prediction
OT  - progression
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflicts of interest in this work.
EDAT- 2023/02/11 06:00
MHDA- 2023/02/11 06:01
PMCR- 2023/01/27
CRDT- 2023/02/10 02:58
PHST- 2022/11/06 00:00 [received]
PHST- 2023/01/11 00:00 [accepted]
PHST- 2023/02/10 02:58 [entrez]
PHST- 2023/02/11 06:00 [pubmed]
PHST- 2023/02/11 06:01 [medline]
PHST- 2023/01/27 00:00 [pmc-release]
AID - 394607 [pii]
AID - 10.2147/DMSO.S394607 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Jan 27;16:275-283. doi: 10.2147/DMSO.S394607. 
      eCollection 2023.